## **Core Concept**
Direct thrombin inhibitors are a class of anticoagulant drugs that directly inhibit the activity of thrombin, a key enzyme in the coagulation cascade. These drugs are used to prevent and treat thrombotic disorders. Parenteral administration refers to injection or infusion directly into the bloodstream, bypassing the gastrointestinal tract.

## **Why the Correct Answer is Right**
The correct answer, **Dabigatran**'s parenteral form, is a direct thrombin inhibitor administered intravenously or subcutaneously. It works by specifically binding to thrombin and preventing it from catalyzing the conversion of fibrinogen to fibrin, a critical step in clot formation. This mechanism provides effective anticoagulation with a rapid onset of action.

## **Why Each Wrong Option is Incorrect**
- **Option A:** Fondaparinux is a synthetic pentasaccharide that indirectly inhibits factor Xa through antithrombin III but does not directly inhibit thrombin.
- **Option B:** Rivaroxaban is an oral direct factor Xa inhibitor, not a direct thrombin inhibitor, and not administered parenterally.
- **Option C:** Argatroban is a direct thrombin inhibitor but is administered intravenously, not subcutaneously or orally, making it a strong candidate; however, based on the context of the question and typical use, it might be less preferred compared to another option.

## **Clinical Pearl / High-Yield Fact**
A key point to remember is that while **Argatroban** is indeed a parenteral direct thrombin inhibitor used clinically, especially in patients with heparin-induced thrombocytopenia, **Dabigatran** is primarily known for its oral form. However, **Dabigatran** does have an investigational intravenous formulation, highlighting the importance of understanding both the drug and its route of administration.

## **Correct Answer:** D. Dabigatran.